Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „rituximab“
Suchtreffer
Begriffe & Kennungen
Ituxredi · 4.8 · IgG levels In the clinical trial evaluating rituximab maintenance treatment in relapsed/refractory follicular
Eintrag öffnenItuxredi · 4.8 · In GPA/MPA Study 1, at 6 months, in the rituximab group, 27%, 58% and 51% of patients with normal immunoglobul
Eintrag öffnenItuxredi · 4.8 · In GPA/MPA Study 2 (adult maintenance study), 7/57 (12%) patients in the rituximab arm experienced at least on
Eintrag öffnenItuxredi · 4.8 · In GPA/MPA Study 2, 30/57 (53%) patients in the rituximab arm experienced infections. The incidence of all gra
Eintrag öffnenItuxredi · 4.8 · In GPA/MPA Study 2, the incidence of all-grade neutropenia was 0% for rituximab-treated patients vs 5% for aza
Eintrag öffnenItuxredi · 4.8 · In PV Study 2, 42 patients (62.7%) in the rituximab arm experienced infections. The most common infections in
Eintrag öffnenItuxredi · 4.8 · In a trial designed to evaluate the safety of a more rapid rituximab infusion in patients with rheumatoid arth
Eintrag öffnenItuxredi · 4.8 · In patients with non-Hodgkin’s lymphoma receiving rituximab in combination with cytotoxic chemotherapy, cases
Eintrag öffnenItuxredi · 4.8 · In placebo-controlled periods of clinical trials, 0.94% (13/1382) of rituximab treated patients and 0.27% (2/7
Eintrag öffnenItuxredi · 4.8 · In studies of rituximab in patients with Waldenstrom’s macroglobulinaemia, transient increases in serum IgM le
Eintrag öffnenItuxredi · 4.8 · Infections In PV Study 1, 14 patients (37%) in the rituximab group experienced treatment-related infections co
Eintrag öffnenItuxredi · 4.8 · Infections Rituximab induces B-cell depletion in about 70-80% of patients but was associated with decreased se
Eintrag öffnenItuxredi · 4.8 · Infusion-related reactions The most frequent adverse reactions following receipt of rituximab in clinical stud
Eintrag öffnenItuxredi · 4.8 · Laboratory abnormalities PV Study 2, in the rituximab arm, transient decreases in lymphocyte count, driven by
Eintrag öffnenItuxredi · 4.8 · Localised candida infections as well as Herpes zoster were reported at a higher incidence in the rituximab-con
Eintrag öffnenItuxredi · 4.8 · Malignancies In GPA/MPA Study 1, the incidence of malignancy in rituximab treated patients in the GPA and MPA
Eintrag öffnenItuxredi · 4.8 · Neutropenia Events of neutropenia were observed with rituximab treatment, the majority of which were transient
Eintrag öffnenItuxredi · 4.8 · Neutropenia In GPA/MPA Study 1, 24% of patients in the rituximab group (single course) and 23% of patients in
Eintrag öffnenItuxredi · 4.8 · Patient subpopulations - Rituximab monotherapy Elderly (65 years and above) The incidence of adverse reactions
Eintrag öffnenItuxredi · 4.8 · Patient subpopulations - rituximab combination therapy Elderly (65 years and above) The incidence of grade 3/4
Eintrag öffnen